Slingshot members are tracking this event:

Phase 3 data of Cimzia (certolizumab pegol) for Moderate-to-severe plaque psoriasis due by end of 1Q 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
DERM Community voting in process

Additional Information

Additional Relevant Details Based on completion of enrollment in all three Phase 3 trials of the psoriasis program, Dermira now expects to announce topline data for the trials by the end of the first quarter of 2017, following completion of the 48-week blinded treatment period in each of the trials. Previously, the company had expected to announce topline data in 2017.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 19, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Data, Cimzia, Plaque Psoriasis, Certolizumab Pegol